NASDAQ:MRSN

Mersana Therapeutics Competitors

$17.14

+0.98 (+6.06 %)

(As of 04/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$16.32

Now: $17.14▼

$17.86

50-Day Range

$15.31

MA: $17.45▼

$19.78

52-Week Range

$7.66

Now: $17.14▼

$29.09

Volume681,219 shs

Average Volume1.05 million shs

Market Capitalization$1.18 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.54

Mersana Therapeutics (NASDAQ:MRSN) Vs. BHVN, AVIR, SAGE, HCM, ARNA, and EBS

Should you be buying MRSN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Mersana Therapeutics, including Biohaven Pharmaceutical (BHVN), Atea Pharmaceuticals (AVIR), Sage Therapeutics (SAGE), Hutchison China MediTech (HCM), Arena Pharmaceuticals (ARNA), and Emergent BioSolutions (EBS).

Mersana Therapeutics vs. Biohaven Pharmaceutical Stock

Biohaven Pharmaceutical (NYSE:BHVN) and Mersana Therapeutics (NASDAQ:MRSN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Earnings and Valuation

This table compares Biohaven Pharmaceutical and Mersana Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven Pharmaceutical	N/A	N/A	$-528,800,000.00	($10.91)	-6.86
Mersana Therapeutics	$42.12 million	28.10	$-28,210,000.00	($0.65)	-26.37

Mersana Therapeutics has higher revenue and earnings than Biohaven Pharmaceutical. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Biohaven Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Biohaven Pharmaceutical has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 2.54, meaning that its share price is 154% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Biohaven Pharmaceutical and Mersana Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven Pharmaceutical	0	2	10	0	2.83
Mersana Therapeutics	0	2	5	0	2.71

Biohaven Pharmaceutical presently has a consensus price target of $96.4545, indicating a potential upside of 28.95%. Mersana Therapeutics has a consensus price target of $26.1667, indicating a potential upside of 52.66%. Given Mersana Therapeutics' higher probable upside, analysts plainly believe Mersana Therapeutics is more favorable than Biohaven Pharmaceutical.

Institutional and Insider Ownership

99.4% of Biohaven Pharmaceutical shares are owned by institutional investors. 19.1% of Biohaven Pharmaceutical shares are owned by company insiders. Comparatively, 5.3% of Mersana Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Biohaven Pharmaceutical and Mersana Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biohaven Pharmaceutical	N/A	-1,091.41%	-120.85%
Mersana Therapeutics	-8,772.91%	-45.16%	-37.53%

Summary

Mersana Therapeutics beats Biohaven Pharmaceutical on 7 of the 13 factors compared between the two stocks.

Mersana Therapeutics vs. Atea Pharmaceuticals Stock

Atea Pharmaceuticals (NASDAQ:AVIR) and Mersana Therapeutics (NASDAQ:MRSN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Earnings & Valuation

This table compares Atea Pharmaceuticals and Mersana Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Mersana Therapeutics	$42.12 million	28.10	$-28,210,000.00	($0.65)	-26.37

Atea Pharmaceuticals has higher earnings, but lower revenue than Mersana Therapeutics.

Analyst Recommendations

This is a summary of recent ratings and price targets for Atea Pharmaceuticals and Mersana Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	0	0	4	0	3.00
Mersana Therapeutics	0	2	5	0	2.71

Atea Pharmaceuticals currently has a consensus price target of $69.3333, indicating a potential upside of 27.03%. Mersana Therapeutics has a consensus price target of $26.1667, indicating a potential upside of 52.66%. Given Mersana Therapeutics' higher probable upside, analysts clearly believe Mersana Therapeutics is more favorable than Atea Pharmaceuticals.

Profitability

This table compares Atea Pharmaceuticals and Mersana Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	N/A	N/A
Mersana Therapeutics	-8,772.91%	-45.16%	-37.53%

Summary

Atea Pharmaceuticals beats Mersana Therapeutics on 4 of the 7 factors compared between the two stocks.

Mersana Therapeutics vs. Sage Therapeutics Stock

Sage Therapeutics (NASDAQ:SAGE) and Mersana Therapeutics (NASDAQ:MRSN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Earnings & Valuation

This table compares Sage Therapeutics and Mersana Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sage Therapeutics	$6.87 million	643.05	$-680,240,000.00	($13.38)	-5.66
Mersana Therapeutics	$42.12 million	28.10	$-28,210,000.00	($0.65)	-26.37

Mersana Therapeutics has higher revenue and earnings than Sage Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Sage Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 2.54, suggesting that its share price is 154% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Sage Therapeutics and Mersana Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sage Therapeutics	0	8	8	0	2.50
Mersana Therapeutics	0	2	5	0	2.71

Sage Therapeutics currently has a consensus price target of $87.0625, indicating a potential upside of 15.06%. Mersana Therapeutics has a consensus price target of $26.1667, indicating a potential upside of 52.66%. Given Mersana Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Mersana Therapeutics is more favorable than Sage Therapeutics.

Profitability

This table compares Sage Therapeutics and Mersana Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sage Therapeutics	-7,706.84%	-63.81%	-56.64%
Mersana Therapeutics	-8,772.91%	-45.16%	-37.53%

Summary

Mersana Therapeutics beats Sage Therapeutics on 8 of the 12 factors compared between the two stocks.

Mersana Therapeutics vs. Hutchison China MediTech Stock

Hutchison China MediTech (NASDAQ:HCM) and Mersana Therapeutics (NASDAQ:MRSN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Institutional & Insider Ownership

33.5% of Hutchison China MediTech shares are owned by institutional investors. 5.3% of Mersana Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for Hutchison China MediTech and Mersana Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hutchison China MediTech	0	0	2	0	3.00
Mersana Therapeutics	0	2	5	0	2.71

Hutchison China MediTech currently has a consensus price target of $40.00, indicating a potential upside of 37.03%. Mersana Therapeutics has a consensus price target of $26.1667, indicating a potential upside of 52.66%. Given Mersana Therapeutics' higher probable upside, analysts clearly believe Mersana Therapeutics is more favorable than Hutchison China MediTech.

Profitability

This table compares Hutchison China MediTech and Mersana Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hutchison China MediTech	N/A	N/A	N/A
Mersana Therapeutics	-8,772.91%	-45.16%	-37.53%

Volatility & Risk

Hutchison China MediTech has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 2.54, meaning that its stock price is 154% more volatile than the S&P 500.

Earnings & Valuation

This table compares Hutchison China MediTech and Mersana Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hutchison China MediTech	$204.89 million	20.74	$-106,020,000.00	($0.80)	-36.49
Mersana Therapeutics	$42.12 million	28.10	$-28,210,000.00	($0.65)	-26.37

Mersana Therapeutics has lower revenue, but higher earnings than Hutchison China MediTech. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Mersana Therapeutics beats Hutchison China MediTech on 8 of the 14 factors compared between the two stocks.

Mersana Therapeutics vs. Arena Pharmaceuticals Stock

Arena Pharmaceuticals (NASDAQ:ARNA) and Mersana Therapeutics (NASDAQ:MRSN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Insider & Institutional Ownership

89.7% of Arena Pharmaceuticals shares are held by institutional investors. 3.1% of Arena Pharmaceuticals shares are held by company insiders. Comparatively, 5.3% of Mersana Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Arena Pharmaceuticals and Mersana Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arena Pharmaceuticals	0	0	15	0	3.00
Mersana Therapeutics	0	2	5	0	2.71

Arena Pharmaceuticals currently has a consensus price target of $92.80, indicating a potential upside of 37.20%. Mersana Therapeutics has a consensus price target of $26.1667, indicating a potential upside of 52.66%. Given Mersana Therapeutics' higher probable upside, analysts clearly believe Mersana Therapeutics is more favorable than Arena Pharmaceuticals.

Profitability

This table compares Arena Pharmaceuticals and Mersana Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arena Pharmaceuticals	N/A	-33.17%	-30.41%
Mersana Therapeutics	-8,772.91%	-45.16%	-37.53%

Risk & Volatility

Arena Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 2.54, indicating that its share price is 154% more volatile than the S&P 500.

Valuation & Earnings

This table compares Arena Pharmaceuticals and Mersana Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arena Pharmaceuticals	$806.43 million	5.06	$397.55 million	$7.69	8.80
Mersana Therapeutics	$42.12 million	28.10	$-28,210,000.00	($0.65)	-26.37

Arena Pharmaceuticals has higher revenue and earnings than Mersana Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Arena Pharmaceuticals beats Mersana Therapeutics on 10 of the 14 factors compared between the two stocks.

Mersana Therapeutics vs. Emergent BioSolutions Stock

Emergent BioSolutions (NYSE:EBS) and Mersana Therapeutics (NASDAQ:MRSN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Insider & Institutional Ownership

80.2% of Emergent BioSolutions shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by company insiders. Comparatively, 5.3% of Mersana Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Emergent BioSolutions and Mersana Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emergent BioSolutions	12.50%	26.68%	12.70%
Mersana Therapeutics	-8,772.91%	-45.16%	-37.53%

Valuation & Earnings

This table compares Emergent BioSolutions and Mersana Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent BioSolutions	$1.11 billion	3.59	$54.50 million	$2.91	25.59
Mersana Therapeutics	$42.12 million	28.10	$-28,210,000.00	($0.65)	-26.37

Emergent BioSolutions has higher revenue and earnings than Mersana Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Emergent BioSolutions and Mersana Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent BioSolutions	0	2	5	0	2.71
Mersana Therapeutics	0	2	5	0	2.71

Emergent BioSolutions currently has a consensus price target of $113.6667, indicating a potential upside of 52.63%. Mersana Therapeutics has a consensus price target of $26.1667, indicating a potential upside of 52.66%. Given Mersana Therapeutics' higher probable upside, analysts clearly believe Mersana Therapeutics is more favorable than Emergent BioSolutions.

Risk & Volatility

Emergent BioSolutions has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 2.54, indicating that its share price is 154% more volatile than the S&P 500.

Summary

Emergent BioSolutions beats Mersana Therapeutics on 9 of the 12 factors compared between the two stocks.